ArticleTurkish journal of medical sciences2025
Predictors of Gleason score upgrading in patients with a biopsy diagnosis of grade group 1 prostate cancer.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Transrectal ultrasound-guided biopsy is the most commonly used method in the diagnostic pathway of prostatic adenocarcinoma. The Gleason score of the tumor is the critical tissue-based determinant of patient management after diagnosis, and the main approach for low risk patients with grade group (GG) 1 disease is active surveillance rather than definitive interventions. However, a fair proportion of these cases are upgraded following radical prostatectomy (RP), if performed. We aimed to investigate the significance of clinicopathological parameters including phosphatase and tensin homolog (PTEN) protein in the prediction of higher final grade at RP in patients with a biopsy diagnosis of GG1 prostatic carcinoma. Materials and methods: Thirty-three patients who underwent robotic-assisted RP for grade GG1 disease at prostate biopsy were evaluated retrospectively. Their clinical, radiological, and pathological features were explored in addition to the final histological grade in RP. Upgrade was defined as any increase in Gleason score from the initial needle biopsy to pathological analysis of the entire surgical specimen. Expression of PTEN in prostate biopsy cores was evaluated through immunohistochemistry. Multivariate logistic regression was performed to detect independent predictors of tumor upgrading from biopsy to RP. Results: The final RP pathology revealed upgrading in 16 patients (48.5%) to GG2 disease. The statistics showed that Prostate Imaging Reporting and Data System score (≤3 vs. 4-5) of the index lesion and the number of involved cores in systematic biopsies (≤2 vs. >2) were the only independent predictors of the presence of a higher grade at RP (p < 0.05). The rate of PTEN loss for upgrading and nonupgrading patients was 25% and 5.9%, respectively, without statistical significance (p = 0.175). Conclusion: Multiparametric magnetic resonance imaging findings and number of tumor positive needle cores are useful parameters to apply for predicting higher grade disease in the RPs of patients with a GG1 tumor diagnosis after a prostate biopsy. Immunohistochemical PTEN analysis, on the other hand, does not provide significant information in this respect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.